Biogen Once Again Accused Of US Tecfidera Skullduggery – This Time By Baltimore
Originator Accused Of Market-Switch Strategy Involving MS Follow-On Vumerity
Biogen resorted to using unlawful, anticompetitive agreements to block the distribution of generic Tecfidera, while it scrambled to switch the market to its follow-on brand, according to another class action lawsuit brought against the originator.
